Last reviewed · How we verify
Capsaicin 1% oral solution
Capsaicin activates TRPV1 receptors, leading to the release of substance P and subsequent pain relief.
Capsaicin activates TRPV1 receptors, leading to the release of substance P and subsequent pain relief. Used for Relief of pain associated with minor cuts, scrapes, and burns.
At a glance
| Generic name | Capsaicin 1% oral solution |
|---|---|
| Sponsor | Georg Kägi, MD |
| Drug class | Topical analgesic |
| Target | TRPV1 |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
The activation of TRPV1 receptors by capsaicin triggers a signaling cascade that ultimately results in the release of substance P, a neurotransmitter involved in pain transmission. This leads to a reduction in pain perception. The exact mechanisms underlying capsaicin's analgesic effects are complex and multifaceted, involving both central and peripheral mechanisms.
Approved indications
- Relief of pain associated with minor cuts, scrapes, and burns
Common side effects
- Skin irritation
Key clinical trials
- Pain Biomarker Study (PHASE1)
- Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain. (PHASE2)
- Improving Diagnostic Standards in Dysphagia
- Capsaicin for Post-stroke Dysphagia (PHASE2)
- Delineating Swallowing Impairment and Decline in ALS
- ATP and P2X3 Receptor in Chronic Cough (NA)
- Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS) (EARLY_PHASE1)
- Sensory Neuromodulation Protocol for the Treatment of Post-stroke Oropharyngeal Dysphagia. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |